Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health Inc (NQ: JAGX )

0.9431 -0.0469 (-4.74%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health Inc

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Jaguar Health's Earnings: A Preview
Jaguar Health (NASDAQ:JAGX) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 /... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians,... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Surgalign Holdings (NASDAQ:SRGA) ... 
Via Benzinga
Why Jaguar Health Shares Are Rising
Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher ... 
Via Benzinga
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX),... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority... 
From Jaguar Health, Inc.
Via AccessWire
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Stealth BioTherapeutics (NASDAQ:MITO 
Via Benzinga
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure... 
From Jaguar Health, Inc.
Via AccessWire
20 Stocks Moving in Thursday's Pre-Market Session
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-... 
Via Benzinga
50 Biggest Movers From Yesterday
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for... 
Via Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing... 
Via Benzinga
NIO Stock Alert: The Steel Deal That Has EV Maker Nio Driving Higher
Nio (NIO) stock is rising higher on Wednesday following news of a deal with Baoshan Iron & Steel and we've got all the details! 
Via InvestorPlace
Chinese Tech Stocks: Why Are DIDI, JD and BABA Moving Higher Today?
Chinese tech stocks are on the move Wednesday and we're diving into the latest news that has these shares heading higher today! 
Via InvestorPlace
JAGX Stock Alert: What Is Going on With Jaguar Health Today?
JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health. 
Via InvestorPlace
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock moved upwards by 69.5% to $4.44 during Wednesday's pre-market session. The market value of their outstanding shares is at $25.2... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning, trader! Let's get this party started with a dive into the biggest pre-market stock movers to watch for Wednesday! 
Via InvestorPlace
15 Stocks Moving in Wednesday's Pre-Market Session
Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share.... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Jaguar Health (NASDAQ:JAGX) stock... 
Via Benzinga
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV... 
Via Benzinga
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs
The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BioRestorative Therapies (NASDAQ:BRTX... 
Via Benzinga
JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher
Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment. 
Via InvestorPlace
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /... 
From Jaguar Health, Inc.
Via AccessWire
Exposures Product Safety
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.